Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Editorial

Inhibitory short synthetic oligodeoxynucleotides and lupus

Zheng Liu1 and Anne Davidson2*

Author Affiliations

1 Department of Microbiology, Columbia University, New York, NY 10032

2 Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY 11030, USA

For all author emails, please log on.

Arthritis Research & Therapy 2009, 11:116  doi:10.1186/ar2726


See related research by Lenert et al., http://arthritis-research.com/content/11/3/R79

Published: 26 June 2009

Abstract

B cells and antigen-presenting cells express a group of intracellular Toll-like receptors (TLRs) that recognize nucleic acids and can be accessed only when apoptotic debris or immune complexes are internalized by B-cell receptors or Fc receptors. This results in rapid cell activation and release of inflammatory mediators that perpetuate the autoantibody response. TLR-7 and TLR-9 are required to generate autoantibodies to RNA and DNA, respectively. Synthetic oligodeoxynucleotides that inhibit the activity of these intracellular TLRs attenuate systemic lupus erythematosus in mouse models and may be of therapeutic benefit in human systemic lupus erythematosus.